Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) announced two abstracts for its lead program PALI-2108 have been selected for poster presentations at major IBD meetings in early 2026. Presentations detail gut-targeted PDE4B inhibition and translational Phase 1a findings in ulcerative colitis.

Events and details: Crohn’s & Colitis Congress (Las Vegas) on Jan 23, 2026 — poster by James Izanec, MD; ECCO 2026 (Stockholm) on Feb 20, 2026 — poster P0989 by James Izanec, MD.

News Market Reaction

-5.14%

6 alerts

-5.14% News Effect

+2.2% Peak Tracked

-11.1% Trough Tracked

-$14M Valuation Impact

$261M Market Cap

0.8x Rel. Volume

On the day this news was published, PALI declined 5.14%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.2% during that session. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $261M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Strategic investment: $500,000 Patent term: 2041 Phase 3 experience: 1,200 patients +5 more

8 metrics

Strategic investment $500,000 Equity investment from Crohn’s & Colitis Foundation for PALI-2108

Patent term 2041 Base term for Japanese composition-of-matter patent for PALI-2108

Phase 3 experience 1,200 patients Size of prior Crohn’s Phase 3 program led by new VP, Clinical Development

Q3 2025 operating expenses $2.9 million Down from $3.6 million year over year

Equity offering proceeds $138 million Underwritten equity offering closed October 2, 2025

Cash balance $133.3 million Cash and cash equivalents as of October 15, 2025

Shelf shares 988,872 shares Shares listed in S-3 shelf registration filed August 15, 2025

Price move -10.26% 24-hour price change prior to abstract announcement

Market Reality Check

Price: $1.66 Vol: Volume 6,909,611 is 21% a...

normal vol

$1.66 Last Close

Volume Volume 6,909,611 is 21% above the 20-day average of 5,732,526, indicating elevated trading ahead of this news. normal

Technical At $1.75, shares trade above the 200-day MA of $1.19 despite a -10.26% daily decline and are 33.71% below the 52-week high.

Peers on Argus

PALI fell 10.26% while only one tracked peer (GRI) appeared in momentum data, do...

1 Down

PALI fell 10.26% while only one tracked peer (GRI) appeared in momentum data, down about 4.44%. Other close peers showed mixed moves, suggesting today’s decline is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Strategic investment	Positive	+5.2%	Equity investment up to $500,000 from Crohn’s & Colitis Foundation.
Dec 30	IP / patent news	Positive	-4.8%	Japanese composition-of-matter patent granted for PALI-2108 to 2041.
Dec 02	Management hire	Positive	-2.1%	Appointment of VP, Clinical Development with extensive Phase 2/3 experience.
Nov 25	Conference participation	Positive	-5.7%	Presentation at Piper Sandler healthcare conference and investor meetings.
Oct 28	Management hire	Positive	+11.4%	New VP, Global Head of Clinical Operations to support PALI-2108 studies.

Pattern Detected

Positive corporate and pipeline updates have frequently seen mixed-to-negative immediate price reactions, with more divergences than alignments.

Recent Company History

Over the past several months, Palisade Bio has focused on advancing PALI-2108 and strengthening its clinical infrastructure. A strategic equity investment of up to $500,000 from the Crohn’s & Colitis Foundation supported development plans and Phase 2 IND submissions targeted for 2026. Patent protection in Japan extending into 2041 broadened IP coverage. Leadership additions in clinical development and operations aimed to support upcoming studies. Against this backdrop, today’s conference-abstract news fits a pattern of steadily building the PALI-2108 story while share reactions have remained inconsistent.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-08-15

Palisade Bio has an active S-3 shelf filed on August 15, 2025, listing 988,872 shares and estimated offering expenses totaling $49,000. The shelf has seen at least one usage via a 424B4 filing on October 2, 2025, indicating capacity and precedent for registered offerings.

Market Pulse Summary

The stock moved -5.1% in the session following this news. A negative reaction despite additional sci...

Analysis

The stock moved -5.1% in the session following this news. A negative reaction despite additional scientific visibility fits a pattern where positive developments sometimes saw selling, with 3 past divergences versus 2 alignments. The abstracts highlight Phase 1a translational findings for PALI-2108 at leading IBD meetings, extending prior IP and funding milestones. Given prior capital raises, including $138 million in gross proceeds and an active S-3, investors may continue to monitor financing usage and upcoming clinical catalysts when assessing longer-term implications.

Key Terms

pde4b, pde4 inhibitor, ulcerative colitis, inflammatory bowel disease, +4 more

8 terms

pde4b medical

"PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a"

PDE4B is a gene that makes an enzyme acting like a brake on a cellular messenger called cAMP, which helps control inflammation and signals in the brain. For investors, PDE4B matters because drugs that block or modify this enzyme can change disease outcomes, create new treatment opportunities, or cause side effects, so progress in PDE4B-targeted research can drive clinical value, regulatory risk, and the commercial potential of biopharma pipelines.

pde4 inhibitor medical

"once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery"

A PDE4 inhibitor is a drug that blocks an enzyme (PDE4) involved in turning off certain cell signals linked to inflammation and brain activity; blocking it lets those signals persist and can reduce inflammation or alter nerve-cell behavior. Investors care because this drug class underlies treatments for conditions like chronic inflammatory and neurological disorders, so clinical trial results, regulatory decisions, or patent news can strongly affect a company’s drug pipeline value and stock outlook.

ulcerative colitis medical

"Rapidly Restores Immune-Epithelial Balance in Ulcerative Colitis Through"

A long-term inflammatory disease that causes repeated sores and irritation in the large intestine, leading to symptoms such as abdominal pain, urgent diarrhea, and fatigue. For investors, it matters because the condition creates a steady need for effective treatments, influences the size of drug and medical-device markets, and makes clinical trial results, regulatory decisions and treatment approvals material to companies’ revenue prospects—like watching for fixes to a recurring leak in an important building system.

inflammatory bowel disease medical

"two premier international inflammatory bowel disease (IBD) meetings"

Inflammatory bowel disease is a group of long‑lasting conditions that cause repeated inflammation of the digestive tract, leading to symptoms like belly pain, diarrhea, bleeding and weight loss. For investors it matters because IBD drives steady demand for medications, ongoing clinical trials, medical devices and diagnostics; think of it as a chronic maintenance market where successful treatments can create predictable, long‑term revenue streams and regulatory milestones can move stock prices.

biomarker medical

"Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

phase 1a medical

"Translational Findings from a Phase 1a Study"

Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.

poster presentation technical

"two abstracts ... selected for poster presentation at two premier"

A poster presentation is a visual display of information, often used to share research findings or ideas at conferences or meetings. It usually consists of a large printed poster that summarizes key points, allowing viewers to quickly understand the main message and ask questions. For investors, it highlights important developments or insights in a clear, accessible way, helping them stay informed about new opportunities or trends.

colon-targeted medical

"PALI-2108, a Colon-Targeted PDE4B Inhibitor, Rapidly Restores"

Colon-targeted describes a medicine, formulation, or delivery system designed to release its active ingredient specifically in the large intestine (colon) rather than earlier in the digestive tract. For investors, this matters because targeted delivery can improve effectiveness, reduce side effects, support niche therapeutic claims, and affect manufacturing complexity, regulatory path, and patent protection—similar to mailing a package directly to a specific room instead of dropping it at the building entrance.

AI-generated analysis. Not financial advice.

PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis

Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026.

Participation details are as follows:

Crohn’s & Colitis Congress^® 2026
January 22–24, 2026 | Las Vegas, NV

Poster Presentation
Session: Poster Hall Reception
Date & Time: Friday, January 23, 2026, 5:00 PM – 6:30 PM PT
Title: PALI-2108, a Colon-Targeted PDE4B Inhibitor, Rapidly Restores Immune-Epithelial Balance in Ulcerative Colitis Through Gut-Selective Lymphocyte Depletion
Presenter: James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio

21st Congress of ECCO – Inflammatory Bowel Diseases 2026
February 18–21, 2026 | Stockholm, Sweden

Poster Presentation
Session: Guided Poster Session
Date & Time: Friday, February 20, 2026, 12:40 – 13:40 CET
Location: Poster Exhibition Hall A
Poster Number: P0989
Title: Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Translational Findings from a Phase 1a Study
Presenter: James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio

“These abstract acceptances underscore the growing scientific and clinical interest in PALI-2108 and its differentiated, gut-targeted approach to treating ulcerative colitis,” said Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio. “We look forward to engaging with the global IBD community and discussing these translational findings across two leading GI forums.”

For more information about the congresses, please visit:
Crohn’s & Colitis Congress^®: crohnscolitiscongress.org
ECCO Congress 2026: ecco-ibd.eu/ecco26/our-congress/overview

About PALI-2108

PALI-2108 is an orally administered, prodrug engineered for local delivery of phosphodiesterase-4 (PDE4) inhibition to the terminal ileum and colon. The prodrug molecule is gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is cleaved by bacterial enzymes to release its active PDE4 inhibitor metabolite directly at the site of inflammation and fibrosis. This targeted and slow-release design prevents absorption through the upper gut, achieves sustained local exposure and a longer half-life that enables once-daily dosing, and is engineered to produce a blunted peak plasma concentration to improve the overall therapeutic index. Together, these properties are intended to maximize anti-inflammatory and anti-fibrotic effects while minimizing systemic exposure and reducing class-related tolerability issues, such as nausea and headache, that have limited systemic PDE4 inhibitors.

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily, ileum- and colon-targeted, locally bioactivated PDE4 inhibitor prodrug being developed for moderate-to-severe Ulcerative Colitis (UC) and fibrostenotic Crohn’s Disease (FSCD), two diseases with limited non-immunosuppressive therapy options. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.

Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is preparing to initiate studies in FSCD to further characterize PALI-2108’s safety, pharmacology and therapeutic benefit across inflammatory bowel disease indications. For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com

FAQ

What will Palisade Bio (PALI) present about PALI-2108 at Crohn’s & Colitis Congress 2026?

A poster on Jan 23, 2026 titled "PALI-2108, a Colon-Targeted PDE4B Inhibitor, Rapidly Restores Immune-Epithelial Balance in Ulcerative Colitis", presented by James Izanec, MD.

When and where is Palisade Bio presenting abstract P0989 for PALI-2108 at ECCO 2026?

Poster P0989 will be presented on Feb 20, 2026 during the Guided Poster Session at ECCO 2026 in Stockholm, Sweden, by James Izanec, MD.

What clinical findings about PALI-2108 are highlighted in the ECCO 2026 poster for PALI?

The ECCO poster describes translational Phase 1a findings showing rapid clinical, histologic, and biomarker improvement in ulcerative colitis with gut-targeted PDE4 inhibition.

Who is the presenter for both PALI-2108 poster presentations for Palisade Bio (PALI)?

Both posters are presented by James Izanec, MD, AGAF, VP, Head of Clinical Development at Palisade Bio.

How can investors or clinicians find more information about Palisade Bio's PALI-2108 conference posters?

Attend the listed poster sessions at Crohn’s & Colitis Congress (Jan 23, 2026) and ECCO (Feb 20, 2026) or check the respective congress program listings for poster P0989.